How might a pharmaceutical company retool its social responsibility strategy amid industry criticisms of runaway drug prices and foot-dragging in developing countries?
How can the structure of accounting balance sheets and income statements help identify social enterprise organizations?
Should a company with a 25-year old corporate social responsibility strategy reinvent its campaign or create a completely new one?
What are the options for a start-up and its founder as she faces the phenomenon known as "Founder's Dilemma"?
How should the World Bank and IMF defend their decision to forgive the debts of the poorest countries?
How should an expanding non-profit without access to venture capital or angel investors finance its growth?
What are the incentives, costs, and risks of adopting guidelines for corporate social responsibility?
How can the leader of Seoul Philharmonic set the stage for continued success?
What is the cost of ethical investing?